Bacterial proteases in IBD and IBS

Postgraduate Medical Journal

Volumn 89, Issue 1047, 2013, Pages 25-33

  Steck, Natalie ^a   Mueller, Kerstin ^a   Schemann, Michael ^a   Haller, Dirk ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CATHEPSIN; CHEMOKINE; CYTOKINE; ELAFIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EXOPEPTIDASE; GELATINASE; GINGIPAIN R; GLYCOSIDASE; GROWTH FACTOR; LEUKOCYTE ELASTASE; METALLOPROTEINASE; MUCIN; OCCLUDIN; PATTERN RECOGNITION RECEPTOR; PRINOMASTAT; PROTEIN KINASE; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE INHIBITOR; THROMBIN; TOLL LIKE RECEPTOR; TRYPSIN; TRYPTASE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; UVOMORULIN; VSL3;

BACTERIAL VIRULENCE; CLINICAL TRIAL (TOPIC); COMMENSAL; DISEASE COURSE; DISEASE PREDISPOSITION; ENTERITIS; ENTEROCOCCUS FAECALIS; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HYPERALGESIA; INFLAMMATORY DISEASE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LUNG CANCER; NERVE CELL STIMULATION; NONHUMAN; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; UNSPECIFIED SIDE EFFECT;

EID: 84871564852     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2011-300775rep     Document Type: Review

References (97)

1. Renz H, von Mutius E, Brandtzaeg P, et al. Gene-environment interactions in chronic inflammatory disease. Nat Immunol 2011;12:273e7.
2. Spiller RC. Overlap between irritable bowel syndrome and inflammatory bowel disease. Dig Dis 2009;(27 Suppl 1):48e54.
3. Ford AC, Talley NJ. IBS in 2010: advances in pathophysiology, diagnosis and treatment. Nat Rev Gastroenterol Hepatol 2011;8:76e8.
4. Birkedal-Hansen H, Moore WG, Bodden MK, et al. Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197e250.
5. Nelson AR, Fingleton B, Rothenberg ML, et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135e49.
6. Baugh MD, Perry MJ, Hollander AP, et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999;117:814e22.
7. Pedersen G, Saermark T, Kirkegaard T, et al. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol 2009;155:257-65.
8. Ravi A, Garg P, Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 2007;13:97e107.
9. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000;47:63e73.
10. Tarlton JF, Whiting CV, Tunmore D, et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol 2000;157:1927e35.
11. Hamilton MJ, Sinnamon MJ, Lyng GD, et al. Essential role for mast cell tryptase in acute experimental colitis. Proc Natl Acad Sci U S A 2011;108:290e5.
12. Menzel K, Hausmann M, Obermeier F, et al. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clin Exp Immunol 2006;146:169e80.
13. Saibeni S, Saladino V, Chantarangkul V, et al. Increased thrombin generation in inflammatory bowel diseases. Thromb Res 2010;125:278e82.
14. Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26e37.
15. Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425e34.
16. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636e47.
17. Tannock GW. The search for disease-associated compositional shifts in bowel bacterial communities of humans. Trends Microbiol 2008;16:488e95.
18. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577e94.
19. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010;156:3205e15.
20. Nell S, Suerbaum S, Josenhans C. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. Nat Rev Microbiol 2010;8:564e77.
21. Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin North Am 2010;24:961e75, ix.
22. Spor A, Koren O, Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 2011;9:279e90.
23. Roka R, Rosztoczy A, Leveque M, et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrheapredominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007;5:550e5.
24. Annahazi A, Gecse K, Dabek M, et al. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain 2009;144:209e17.
25. Bustos D, Negri G, De Paula JA, et al. Colonic proteinases: increased activity in patients with ulcerative colitis. Medicina (B Aires) 1998;58:262e4.
26. Gecse K, Roka R, Ferrier L, et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008;57:591e9.
27. Macfarlane GT, Allison C, Gibson SA, et al. Contribution of the microflora to proteolysis in the human large intestine. J Appl Bacteriol 1988;64:37e46.
28. Pruteanu M, Hyland NP, Clarke DJ, et al. Degradation of the extracellular matrix components by bacterial-derived metalloproteases: implications for inflammatory bowel diseases. Inflamm Bowel Dis 2010;17:1189e200.
29. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010;464:59e65.
30. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 2008;105:16731e6.
31. Macfarlane GT, Blackett KL, Nakayama T, et al. The gut microbiota in inflammatory bowel disease. Curr Pharm Des 2009;15:1528e36.
32. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol 2008;14:401e7.
33. McGuckin MA, Eri R, Simms LA, et al. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15:100e13.
34. Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009;136:551e63.
35. Warfel JM, Steele AD, D'Agnillo F. Anthrax lethal toxin induces endothelial barrier dysfunction. Am J Pathol 2005;166:1871e81.
36. Babbin BA, Sasaki M, Gerner-Schmidt KW, et al. The bacterial virulence factor lymphostatin compromises intestinal epithelial barrier function by modulating rho GTPases. Am J Pathol 2009;174:1347e57.
37. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 2005;18:247e63.
38. Grys TE, Siegel MB, Lathem WW, et al. The StcE protease contributes to intimate adherence of enterohemorrhagic Escherichia coli O157:H7 to host cells. Infect Immun 2005;73:1295e303.
39. Wu S, Rhee KJ, Zhang M, et al. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and gamma-secretasedependent E-cadherin cleavage. J Cell Sci 2007;120:1944e52.
40. Hoy B, Lower M, Weydig C, et al. Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E-cadherin to disrupt intercellular adhesion. EMBO Rep 2010;11:798e804.
41. Azghani AO, Gray LD, Johnson AR. A bacterial protease perturbs the paracellular barrier function of transporting epithelial monolayers in culture. Infect Immun 1993;61:2681e6.
42. Rudack C, Sachse F, Albert N, et al. Immunomodulation of nasal epithelial cells by Staphylococcus aureus-derived serine proteases. J Immunol 2009;183:7592e601.
43. Wu Z, Nybom P, Magnusson KE. Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction-associated proteins occludin and ZO-1. Cell Microbiol 2000;2:11e17.
44. Steck N, Hoffmann M, Sava IG, et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. Gastroenterology
45. Schultsz C, Van Den Berg FM, Ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology 1999;117:1089e97.
46. Fyderek K, Strus M, Kowalska-Duplaga K, et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J Gastroenterol 2009;15:5287e94.
47. Rhodes JM, Gallimore R, Elias E, et al. Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease. Gut 1985;26:761e5.
48. Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol 2010;105:2420e8.
49. McGuckin MA, Linden SK, Sutton P, et al. Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011;9:265e78.
50. Vergnolle N. Clinical relevance of proteinase activated receptors (PARs) in the gut. Gut 2005;54:867e74.
51. Amadesi S, Bunnett N. Protease-activated receptors: protease signaling in the gastrointestinal tract. Curr Opin Pharmacol 2004;4:551e6.
52. Karanjia R, Spreadbury I, Bautista-Cruz F, et al. Activation of protease-activated receptor-4 inhibits the intrinsic excitability of colonic dorsal root ganglia neurons. Neurogastroenterol Motil 2009;21:1218e21.
53. Asfaha S, Cenac N, Houle S, et al. Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. Br J Pharmacol 2007;150:176e85.
54. Auge C, Balz-Hara D, Steinhoff M, et al. Protease-activated receptor-4 (PAR 4): a role as inhibitor of visceral pain and hypersensitivity. Neurogastroenterol Motil 2009;21:1189ee107.
55. Mueller K, Michel K, Krueger D, et al. Activity of Protease-Activated Receptors in the Human Submucous Plexus. Gastroenterology, 2011, doi:10.1053/j.gastro.2011.08.034.
56. Lourbakos A, Chinni C, Thompson P, et al. Cleavage and activation of proteinase-activated receptor-2 on human neutrophils by gingipain-R from Porphyromonas gingivalis. FEBS Lett 1998;435:45e8.
57. Lourbakos A, Potempa J, Travis J, et al. Arginine-specific protease from Porphyromonas gingivalis activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion. Infect Immun 2001;69:5121e30.
58. Lourbakos A, Yuan YP, Jenkins AL, et al. Activation of proteaseactivated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. Blood 2001;97:3790e7.
59. Holzhausen M, Spolidorio LC, Ellen RP, et al. Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. Am J Pathol 2006;168:1189e99.
60. Dulon S, Leduc D, Cottrell GS, et al. Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. Am J Respir Cell Mol Biol 2005;32:411e19.
61. Kida Y, Higashimoto Y, Inoue H, et al. A novel secreted protease from Pseudomonas aeruginosa activates NF-kappaB through protease-activated receptors. Cell Microbiol 2008;10:1491e504.
62. Kida Y, Inoue H, Shimizu T, et al. Serratia marcescens serralysin induces inflammatory responses through protease-activated receptor 2. Infect Immun 2007;75:164e74.
63. Asokananthan N, Graham PT, Stewart DJ, et al. House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. J Immunol 2002;169:4572e8.
64. Sun G, Stacey MA, Schmidt M, et al. Interaction of mite allergens Der p3 and Der p9 with protease-activated receptor-2 expressed by lung epithelial cells. J Immunol 2001;167:1014e21.
65. Katz J, Sambandam V, Wu JH, et al. Characterization of Porphyromonas gingivalis-induced degradation of epithelial cell junctional complexes. Infect Immun 2000;68:1441e9.
66. Sugawara S, Nemoto E, Tada H, et al. Proteolysis of human monocyte CD14 by cysteine proteinases (gingipains) from Porphyromonas gingivalis leading to lipopolysaccharide hyporesponsiveness. J Immunol 2000;165:411e18.
67. Azghani AO. Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Am J Respir Cell Mol Biol 1996;15:132e40.
68. de Zoete MR, Bouwman LI, Keestra AM, et al. Cleavage and activation of a Toll-like receptor by microbial proteases. Proc Natl Acad Sci U S A 2011;108:4968e73.
69. Brunn GJ, Bungum MK, Johnson GB, et al. Conditional signaling by Toll-like receptor 4. Faseb J 2005;19:872e4.
70. Cario E, Golenbock DT, Visintin A, et al. Trypsin-sensitive modulation of intestinal epithelial MD-2 as mechanism of lipopolysaccharide tolerance. J Immunol 2006;176:4258e66.
71. Moretti S, Bellocchio S, Bonifazi P, et al. The contribution of PARs to inflammation and immunity to fungi. Mucosal Immunol 2008;1:156e68.
72. van Roy F, Berx G. The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 2008;65:3756e88.
73. Mengaud J, Ohayon H, Gounon P, et al. E-cadherin is the receptor for internalin, a surface protein required for entry of L. monocytogenes into epithelial cells. Cell 1996;84:923e32.
74. Phan QT, Myers CL, Fu Y, et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007;5:e64.
75. Moreno-Ruiz E, Galan-Diez M, Zhu W, et al. Candida albicans internalization by host cells is mediated by a clathrin-dependent mechanism. Cell Microbiol 2009;11:1179e89.
76. Noe V, Fingleton B, Jacobs K, et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001;114:111e18.
77. Maretzky T, Reiss K, Ludwig A, et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A 2005;102:9182e7.
78. Huguenin M, Muller EJ, Trachsel-Rosmann S, et al. The metalloprotease meprinbeta processes E-cadherin and weakens intercellular adhesion. PLoS One 2008;3:e2153.
79. Freour T, Jarry A, Bach-Ngohou K, et al. TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. Int J Mol Med 2009;23:41e8.
80. Kirkegaard T, Pedersen G, Saermark T, et al. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol 2004;135:146e53.
81. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281e4.
82. Forsyth CB, Banan A, Farhadi A, et al. Regulation of oxidantinduced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther 2007;321:84e97.
83. Kenny PA. Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opin Ther Targets 2007;11:1287e98.
84. Isozaki Y, Yoshida N, Kuroda M, et al. Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis. Scand J Gastroenterol 2006;41:944e53.
85. Senda S, Fujiyama Y, Bamba T, et al. Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 1993;32:350e4.
86. Sykes AP, Bhogal R, Brampton C, et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:1535e42.
87. Di Sebastiano P, di Mola FF, Artese L, et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 2001;63:234e9.
88. Medina C, Santana A, Paz MC, et al. Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol 2006;79:954e62.
89. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842e9.
90. Rolland C, Motta J-P, Rousset P, et al. Increased proteolytic activity at mucosal surfaces in IBD Patients: a possible role for elafin. Gastroenterology 2011;140:S-695.
91. Motta JP, Magne L, Descamps D, et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011;140:1272e82.
92. Kim JA, Choi SC, Yun KJ, et al. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm Bowel Dis 2003;9:224e9.
93. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687e96.
94. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103e8.
95. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-tomoderate ulcerative colitis. Med Sci Monit 2004;10:PI126e31.
96. Kunze WA, Mao YK, Wang B, et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calciumdependent potassium channel opening. J Cell Mol Med 2009;13:2261e70.
97. von Schillde M-A, Hãrmannsperger G, Alpert C-A, et al. T2025 probiotic-derived lactocepin degrades the pro-inflammatory chemokine IP-10: impact on chronic intestinal inflammation. Gastroenterology 2010;138:S-615e16.